The Committee for Medicinal Products for Human Use of the European Medicine Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with doxorubicin, vinblastine, and dacarbazine—or AVD—in adult patients with previously untreated CD30+ stage 3 Hodgkin lymphoma.
Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.
